TY - JOUR T1 - A clinical MALDI-ToF Mass spectrometry assay for SARS-CoV-2: Rational design and multi-disciplinary team work JF - medRxiv DO - 10.1101/2020.08.22.20176669 SP - 2020.08.22.20176669 AU - Ray K Iles AU - Raminta Zmuidinaite AU - Jason K Iles AU - George Carnell AU - Alex Sampson AU - Jonathan L Heeney Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/22/2020.08.22.20176669.abstract N2 - The COVID-19 pandemic caused by the SARS-CoV-2 Coronavirus has stretched national testing capacities to breaking points in almost all countries of the world. The need to rapidly screen vast numbers of a country’s population in order to control the spread of the infection is paramount. However, the logistical requirement for reagent supply (and associated cost) of RT-PCR based testing (the current front-line test) have been hugely problematic. Mass spectrometry-based methods using swab and gargle samples have been reported with promise, but have not approached the task from a systematic analysis of the entire diagnostic process. Here, the pipeline from sample processing, the biological characteristics of the pathogen in human biofluid, the downstream bio- and physical-chemistry and the all-important data processing with clinical interpretation and reporting, are carefully compiled into a single high throughput and reproducible rapid process.Utilizing MALDI-ToF mass spectrometric detection to viral envelope glycoproteins in a systems biology – multidisciplinary team approach, we have achieved a multifaceted clinical MALDI ToF MS screening test, primarily (but not limited to) SARS-CoV-2, with direct applicable to other future epidemics/pandemics that may arise.The clinical information generated not only includes SARS-CoV-2 Coronavirus detection – (Spike protein fragments S1, S2b, S2a peaks), but other respiratory viral infections detected as well as an assessment of generalised oral upper respiratory immune response (elevated total Ig light chain peak) and a measure of the viral immune response (elevated intensity of IgA heavy chain peak).The advantages of the method include; 1) ease of sampling, 2) speed of analysis, and much reduced cost of testing. These features reveal the diagnostic utility of MALDI-ToF mass spectrometry as a powerful and economically-attractive global solution.Competing Interest StatementR. Zmuidinaite , G Carnell, A Sampson, J L Heeney declare no conflicts of interest R.K. Iles & J.K. Iles have submitted a patent application on solubilization detergents formulations for use in mass spectrometry. Clinical TrialDevelopment study so not a formal trial but now being adopted under UK government Falcon and HICCFunding StatementInternally funded by MAPSciences Ltd Department of Veterinary medicine Cambridge University NISAD Lund SwedenAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NISAD Lund Sweden MAPScienceAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw spectral data (anonymised) is available on request ER -